Mustang Bio, City of Hope CAR-T therapy extends survival in phase 1 glioblastoma trial, Fierce Biotech, March 12, 2024
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma, BioSpace, March 7, 2024
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial, MarketWatch, March 7, 2024
Mazyar Shadman, MD, on Evaluating MB-106 in a Multicenter Study, CGTLive, December 21, 2023
Mustang Bio receives FDA clearance for combined brain tumor treatment, Worcester Business Journal, October 26, 2023
Mustang Bio’s CAR/Oncolytic Virus Combo Cleared for Glioblastoma/Astrocytoma Trial, CGTLive, October 26, 2023
MB-106 induces response in indolent lymphoma, Healio / HemOnc Today, August 20, 2023
Preliminary Outcomes Unveiled from Ongoing Phase 1/2 Clinical Study of MB-106 CAR-T Cell Therapy, as Declared by Mustang Bio, Pharma Focus America, August 17, 2023
MB-106 Shows Potential in Indolent Lymphoma, CGTLive, August 16, 2023
MB-106 Shows Continued Activity in Relapsed/RefractoryIndolent Non-Hodgkin Lymphoma, OncLive, August 16, 2023
Mustang Bio to Discuss MB-106 Development Plan With FDA After Positive Data in Lymphoma, Precision Oncology News, August 16, 2023
MB-106 Generates Responses in BTK Inhibitor–Refractory Waldenström Macroglobulinemia, OncLive, June 26, 2023
Mustang Bio’s CAR-T MB-106 Achieves Responses in Waldenstrom Macroglobulinemia, Follicular Lymphoma, CGTLive, June 17, 2023